Budapest, Hungary

Éva Pécsi

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 13.0

ph-index = 1


Company Filing History:


Years Active: 2012-2017

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Éva Pécsi: Innovator in Pharmaceutical Chemistry

Introduction

Éva Pécsi is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of processes for drug preparation. His work has led to advancements in the production of high-purity medications, which are essential for effective treatment.

Latest Patents

Éva Pécsi holds a patent for a "Process for preparation of high-purity meloxicam and meloxicam potassium salt." This invention provides a method for producing high-purity meloxicam, a non-steroidal anti-inflammatory drug. The process involves reacting meloxicam raw product with a solution of potassium hydroxide or potassium carbonate, resulting in high-purity meloxicam potassium salt monohydrate. This salt is then treated with mineral or organic acid to yield high-purity meloxicam.

Career Highlights

Throughout his career, Éva Pécsi has worked with prominent companies in the pharmaceutical industry. He has been associated with Egis Gyógyszergyár Nyilvánosan Muködö Részvénytársaság and Egis Gyógyszergyár Zrt., where he has contributed to various innovative projects. His expertise in pharmaceutical processes has been instrumental in enhancing the quality of drug formulations.

Collaborations

Éva Pécsi has collaborated with several professionals in his field, including Tibor Mezei and Gyula Simig. These collaborations have fostered a productive environment for innovation and have led to the successful development of new pharmaceutical processes.

Conclusion

Éva Pécsi's contributions to pharmaceutical chemistry, particularly through his patent for high-purity meloxicam, highlight his role as an innovator in the industry. His work continues to impact the field positively, ensuring the availability of high-quality medications for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…